Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Radiopharm Theranostics announced positive Phase 1 trial results for RAD301, a novel Gallium-68 labeled peptide targeting αvβ6-integrin in pancreatic ductal adenocarcinoma (PDAC) patients. The trial demonstrated favorable safety, significant tumor uptake, and selective biodistribution, indicating RAD301’s potential to improve pancreatic cancer imag…